• Source: Elezanumab

Elezanumab (development names AE12-1Y-QL and ABT-555) is a fully human monoclonal antibody developed by AbbVie against repulsive guidance molecule A (RGMa). It has been tested in people with multiple sclerosis and acute ischemic stroke.




References

Kata Kunci Pencarian:

• Elezanumab
• List of therapeutic monoclonal antibodies